Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C26H24F3N7O3S |
|||
Molecular Weight | 571.57 | CAS No. | 1439399-58-2 | |
Solubility (25°C)* | In vitro | DMSO | 100 mg/mL (174.95 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | Telaglenastat (CB-839) is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. CB-839(Telaglenastat) inudces autophagy and has antitumor activity. Phase 1. | ||
---|---|---|---|
Targets |
|
||
In vitro | CB-839 exhibits time-dependent and slowly reversible kinetics. IC50 values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for-1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. CB-839 has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D.[1] | ||
In vivo | In the mouse TNBC model, single agent CB-839 (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, CB-839 alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, combination of CB-839 (200 mg/kg, p.o.) with paclitaxel (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors resulting in a TGI relative to vehicle control of 100%.[1] |
Kinase Assay: |
|
---|---|
Cell Assay: |
|
Animal Study: |
|
Data from [Data independently produced by , , Haematologica, 2018, doi:10.3324/haematol.2018.204701]
Data from [Data independently produced by , , Br J Cancer, 2018, 118(8):1074-1083]
Data from [Data independently produced by , , Biochem Pharmacol, 2018, 156:204-214]
Data from [Data independently produced by , , Tumor Biol, 2016, 37:11007-11015.]
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines [ Biochem Pharmacol, 2024, S0006-2952(24)00144-8] | PubMed: 38522556 |
ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression [ Int J Mol Sci, 2024, 25(6)3273] | PubMed: 38542254 |
RBM4 dictates ESCC cell fate switch from cellular senescence to glutamine-addiction survival through inhibiting LKB1-AMPK-axis [ Signal Transduct Target Ther, 2023, 8(1):159] | PubMed: 37080995 |
An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression [ Cancer Discov, 2023, 13(7):1696-1719] | PubMed: 37140445 |
Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC [ J Thorac Oncol, 2023, S1556-0864(23)00197-1] | PubMed: 36958689 |
Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients [ Nat Commun, 2023, 10.1038/s41467-023-42881-4] | PubMed: 37938561 |
Alanine supplementation exploits glutamine dependency induced by SMARCA4/2-loss [ Nat Commun, 2023, 14(1):2894] | PubMed: 37210563 |
SLC7A11 expression level dictates differential responses to oxidative stress in cancer cells [ Nat Commun, 2023, 14(1):3673] | PubMed: 37339981 |
Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer [ Cancer Commun (Lond), 2023, 43(8):909-937] | PubMed: 37434399 |
Lipophagy-mediated cholesterol synthesis inhibition is required for the survival of hepatocellular carcinoma under glutamine deprivation [ Redox Biol, 2023, 63:102732] | PubMed: 37150151 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.